There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer

The hype around hyperthermic intraperitoneal chemotherapy (HIPEC) started two decades ago when a randomized trial comparing surgery and HIPEC against palliative chemotherapy only in patients with colorectal cancer showed favorable results. In ovarian cancer, data from three prospective randomized co...

ver descrição completa

Detalhes bibliográficos
Autores: Schwameis, R. (Richard)|||/items/00aca49d-50c3-4612-8b2d-77abd8cdca7d, Chiva-de-Agustín, L. (Luis)|||/items/5aab5671-f48d-4295-8ae0-c8c88221e1f1, Harter, P. (P.)|||/items/262661b2-4b5b-463b-a599-bbc50796f3ca
Formato: artículo
Fecha de publicación:2022
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/123856
Acesso em linha:https://hdl.handle.net/10171/123856
Access Level:acceso abierto
Palavra-chave:Cystadenocarcinoma
Cytoreduction surgical procedures
General surgery
Operative
Ovarian cancer
Serous
Surgical procedures
Descrição
Resumo:The hype around hyperthermic intraperitoneal chemotherapy (HIPEC) started two decades ago when a randomized trial comparing surgery and HIPEC against palliative chemotherapy only in patients with colorectal cancer showed favorable results. In ovarian cancer, data from three prospective randomized controlled trials and several retrospective trials are available.

Registos relacionados